Adlai Nortye Group Ltd. American
Adlai Nortye Group Ltd. American Depositary Shares is the U.S.-traded share class of Adlai Nortye Ltd., a clinical-stage biotechnology company focused on developing cancer therapies. The company’s current work centers on advancing oncology drug candidates through clinical research, with programs spanning targeted treatments designed to address different tumor types and treatment settings. Its portfolio includes investigational therapies aimed at modulating key cancer pathways and the tumor microenvironment, reflecting a focus on precision medicine approaches in oncology. Adlai Nortye serves as a small but active participant in the global biopharmaceutical market, with operations connected to drug discovery, preclinical development, and late-stage clinical testing. The American Depositary Shares give U.S. investors access to the company’s ordinary shares through a structure commonly used by international life sciences firms.
$11.03
-$1.06 (-8.77%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-713.96% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -52.49% to -71.32%, capital efficiency is deteriorating. Negative free cash flow of -$34M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$5M
Net Income (TTM)
-$36M
▲ +31.5% YoY
Op. Margin
-713.96%
ROIC
-71.32%
▼ -18.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$34M
▲ +35.3% YoY
Op. Cash Flow (TTM)
-$33M
▲ +35.4% YoY
Net Debt
$18M
Cash & Equiv.
$8M
Continue Research
Is Adlai Nortye Group Ltd. American (ANL) overvalued?
Adlai Nortye Group Ltd. American (ANL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Adlai Nortye Group Ltd. American scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Adlai Nortye Group Ltd. American a high-quality business?+
Adlai Nortye Group Ltd. American scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -714.0% operating margin and a -71.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Adlai Nortye Group Ltd. American a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh ANL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.